HKSE:01541 (China)
Â
Ordinary Shares - Class H
HK$
3.5
+0.34 (+10.94%)
Aug 11
Business Description
ImmuneOnco Biopharmaceuticals (Shanghai) Inc
ISIN : CNE100006624
Share Class Description:
HKSE:01541: Ordinary Shares - Class HTotal Employee Number:
202Compare
Compare
Traded in other countries / regions
01541.Hong KongR9Z.Germany Index Membership
Hong Kong Stock Connect IPO Date
2023-09-05Description
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has designed a robust pipeline of over ten drug candidates with 12 ongoing clinical programs., featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.46 | |||||
Equity-to-Asset | 0.72 | |||||
Debt-to-Equity | 0.29 | |||||
Debt-to-EBITDA | -1.07 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 1.41 | |||||
Beneish M-Score | 31.74 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 491.1 | |||||
3-Year EBITDA Growth Rate | 22.6 | |||||
3-Year EPS without NRI Growth Rate | 21.4 | |||||
3-Year FCF Growth Rate | 11.4 | |||||
3-Year Book Growth Rate | -4.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 77.58 | |||||
9-Day RSI | 63.92 | |||||
14-Day RSI | 56.65 | |||||
3-1 Month Momentum % | -14.57 | |||||
6-1 Month Momentum % | -22.77 | |||||
12-1 Month Momentum % | -69.68 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.83 | |||||
Quick Ratio | 3.83 | |||||
Cash Ratio | 3.69 | |||||
Days Sales Outstanding | 0.02 | |||||
Days Payable | 9123.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5 | |||||
Shareholder Yield % | -29.17 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 99.28 | |||||
Operating Margin % | -137.51 | |||||
Net Margin % | -140.99 | |||||
EBITDA Margin % | -138 | |||||
FCF Margin % | -131.59 | |||||
OCF Margin % | -130.74 | |||||
ROE % | -32.93 | |||||
ROA % | -23.65 | |||||
ROIC % | -83.8 | |||||
3-Year ROIIC % | 270.16 | |||||
ROC (Joel Greenblatt) % | -500.69 | |||||
ROCE % | -31.02 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 8.54 | |||||
PB Ratio | 1.72 | |||||
Price-to-Tangible-Book | 1.72 | |||||
EV-to-EBIT | -1.87 | |||||
EV-to-EBITDA | -1.87 | |||||
EV-to-Revenue | 2.58 | |||||
EV-to-FCF | -1.96 | |||||
| Price-to-Net-Current-Asset-Value | 1.82 | |||||
| Price-to-Net-Cash | 1.92 | |||||
Earnings Yield (Greenblatt) % | -53.48 | |||||
FCF Yield % | -14.88 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 170.009 | ||
| EPS (TTM) (HK$) | -0.581 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 74.88 | ||
| 14-Day RSI | 56.65 | ||
| 14-Day ATR (HK$) | 0.238937 | ||
| 20-Day SMA (HK$) | 3.25125 | ||
| 12-1 Month Momentum % | -69.68 | ||
| 52-Week Range (HK$) | 2.8 - 16.8 | ||
| Shares Outstanding (Mil) | 429.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Frequently Asked Questions
What is ImmuneOnco Biopharmaceuticals (Shanghai) Inc(HKSE:01541)'s stock price today?
The current price of HKSE:01541 is HK$3.50. The 52 week high of HKSE:01541 is HK$16.80 and 52 week low is HK$2.80.
When is next earnings date of ImmuneOnco Biopharmaceuticals (Shanghai) Inc(HKSE:01541)?
The next earnings date of ImmuneOnco Biopharmaceuticals (Shanghai) Inc(HKSE:01541) is .
Does ImmuneOnco Biopharmaceuticals (Shanghai) Inc(HKSE:01541) pay dividends? If so, how much?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc(HKSE:01541) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on ImmuneOnco Biopharmaceuticals (Shanghai) Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers